Halper Sadeh LLC is investigating the fairness of Roche’s buyout of 89bio, as the deal raises important questions about shareholder value and potential future earnings. This scrutiny is crucial for investors to ensure they receive just compensation for their stakes in the company.
NEW YORK–(BUSINESS WIRE)–Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of 89bio, Inc. (NASDAQ: ETNB) to Roche is fair to 89bio shareholders. Under the terms of the proposed transaction, 89bio shareholders will receive $14.50 per share in cash at closing, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $6.00 per share in cash upon achievement of specified milestones. Halper Sadeh encourages 89bio sha
Source: Original Press Release
